Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Yahya AshrafHanane MansouriValérie Laurent-MathaLindsay B AlcarazPascal RogerSéverine GuiuDanielle DerocqGautier RobinHenri-Alexandre MichaudHelène DelpechMarta JarlierMartine PugnièreBruno RobertAnthony PuelLucie MartinFlavie LandomielThomas BourquardOussama AchourIngrid Fruitier-ArnaudinAlexandre PichardEmmanuel DeshayesAndrei TurtoiAnne PouponJoëlle Simony-LafontaineFlorence Boissière-MichotNelly PirotFlorence BernexWilliam JacotStanislas du ManoirCharles TheilletJean-Pierre PougetIsabelle Navarro-TeulonNathalie BonnefoyAndré PèlegrinThierry ChardèsPierre MartineauEmmanuelle Liaudet-CoopmanPublished in: Journal for immunotherapy of cancer (2019)
Cath-D is a tumor-specific extracellular target in TNBC suitable for antibody-based therapy. Immunomodulatory antibody-based strategy against cath-D is a promising immunotherapy to treat patients with TNBC.